Author Archive

Overview of WHO Negotiations

https://jamesroguski.substack.com/p/an-overview-of-the-who-negotiations?

An Overview of the WHO Negotiations

After nearly two years of reporting on the WHO, many people have requested that I provide an overview of what is going on with the WHO negotiations. Please share this information far and wide.

 
JAMES ROGUSKI
JAN 1, 2024
 

IMPORTANT POINTS:

The best way to understand this issue is to watch the videos below.

Many people have confused the different documents that are involved.

  1. The proposed amendments to the International Health Regulations (2022 and 2024)

  2. The proposed “Pandemic Agreement,” which most people refer to as the “Pandemic Treaty,” but is really a Framework Convention (which is a really, really bad idea).

THE 2022 AMENDMENTS TO THE IHR

The WHO has fraudulently claimed that it adopted amendments to the International Health Regulations on May 28, 2022, but it never bothered to actually conduct a vote.

This should be a worldwide scandal, but nearly everyone is ignoring this blatant fraud. CLICK HERE FOR DETAILS

THE 2024 AMENDMENTS TO THE IHR

Over 300 amendments to the International Health Regulations are currently being negotiated. These negotiations have been conducted in secret for over one year. The originally proposed amendments are available HERE. No updated or revised versions have ever been made public.

The deadline for the WHO to present the final package of targeted amendments is January 27, 2024. They have announced publicly that they are NOT going to meet their deadline. This should be all over the news, but practically no one is talking about it.

NO final version of the amendments has been provided. To learn more about the fast approaching deadline, CLICK HERE.

The next meeting of the Working Group for amendments to the International Health Regulations (WGIHR) is scheduled for February 5-9, 2024. LINK

Go to link for details.

For more:

Category:

Activism, Treatment, vaccines, Viruses

Natural Immunity Protects Against Severe Infection & Statistical Evidence In Support of Early Outpatient COVID Treatment Protocols

https://petermcculloughmd.substack.com/p/natural-immunity-protects-against

Natural Immunity Protects Against Severe Infection Throughout Pandemic

Study Indicates Prior Infection, Milder Strains were Protective while Vaccination Backfired and Increased Risk of Hospitalization

PETER MCCULLOUGH, MD
JAN 4, 2024

When a patient called from from 2022 forward with a new episode of COVID-19, the first thing I asked them was “have you had COVID-19 in the past?” This is such an important question because that natural immunity has been powerful in mitigating risks of future COVID-19 hospitalization.

Uuskula et al leveraged a nationwide database in Estonia to give critical information on the changing waves of COVID-19 infection:

Abstract

A large proportion of the world’s population has some form of immunity against SARS-CoV-2, through either infection (‘natural’), vaccination or both (‘hybrid’). This retrospective cohort study used data on SARS-CoV-2, vaccination, and hospitalization from national health system from February 2020 to June 2022 and Cox regression modeling to compare those with natural immunity to those with no (Cohort1, n = 94,982), hybrid (Cohort2, n = 47,342), and vaccine (Cohort3, n = 254,920) immunity.

  • In Cohort 1, those with natural immunity were at lower risk for infection during the Delta (aHR 0.17, 95%CI 0.15–0.18) and higher risk (aHR 1.24, 95%CI 1.18–1.32) during the Omicron period than those with no immunity. Natural immunity conferred substantial protection against COVID-19-hospitalization.
  • Cohort 2—in comparison to natural immunity hybrid immunity offered strong protection during the Delta (aHR 0.61, 95%CI 0.46–0.80) but not the Omicron (aHR 1.05, 95%CI 0.93–1.1) period. COVID-19-hospitalization was extremely rare among individuals with hybrid immunity.
  • In Cohort 3, individuals with vaccine-induced immunity were at higher risk than those with natural immunity for infection (Delta aHR 4.90, 95%CI 4.48–5.36; Omicron 1.13, 95%CI 1.06–1.21) and hospitalization (Delta aHR 7.19, 95%CI 4.02–12.84).
These results show that risk of infection and severe COVID-19 are driven by personal immunity history and the variant of SARS-CoV-2 causing infection.

https://drlf.substack.com/p/presentation-statistical-evidence

Presentation: Statistical evidence from case series data in support of early outpatient COVID-19 treatment protocols

by Eleftherios Gkioulekas, Ph.D.
JAN 1, 2024
Transcript
On March 23, 2020, Dr. Vladimir Zelenko announced his treatment protocol for COVID-19, which consisted of risk stratifying patients as high-risk vs low-risk, and treating high-risk patients with a multi-drug therapy consisting of a 5 day treatment with hydroxychloroquine, azithromycin, and zinc sulfate.  Dr. Zelenko defined three categories of high-risk patients: (a) all patients older than 60 years; (b) patients that are immunocompromised or have comorbidities or have BMI>30kg/m2; (c) all patients not satisfying the previous two conditions that develop shortness of breath.
Dr. Zelenko’s protocol was incrementally improved by including a quercetin protocol for low-risk patients to reduce severity of symptoms, the adoption of dexamethasone and nebulized bdesonide at the beginning of May 2020, and the adoption of the blood thinner Eliquis at the end of May 2020, and the beginning of June 2020.  With these adaptations, Dr. Zelenko’s protocol evolved into what is now the well-known McCullough protocol [1].
(See link for paper & presentation)
_____________
For More:

Category:

research, Treatment, Viruses

Medical Gaslighting and Lyme Disease: The Patient Experience

healthcare-12-00078

Medical Gaslighting and Lyme Disease: The Patient Experience

Jennifer L. Fagen 1, *, Jeremy A. Shelton 2 and Jenna Luché-Thayer 3

Abstract:

Even though there are approximately half a million new cases of Lyme disease in the US annually, according to the CDC, it is often undiagnosed or misdiagnosed, which can result in a chronic, multisystemic condition. Lyme disease is a recognized public health threat and is a designated “notifiable disease”. As such, Lyme disease is mandated to be reported by the CDC. Despite this, both acute and chronic Lyme disease (CLD) have been relegated to the category of “contested illnesses”, which can lead to medical gaslighting. By analyzing results from an online survey of respondents with Lyme disease (n = 986), we elucidate the lived experiences of people who have been pushed to the margins of the medical system by having their symptoms attributed to mental illness, anxiety, stress, and aging. Further, respondents have had their blood tests and erythema migrans (EM) rashes discounted and were told that CLD simply does not exist. As a result, a series of fruitless consultations often result in the delay of a correct diagnosis, which has deleterious consequences. This is the first study that addresses an extensive range of gaslighting techniques experienced by this patient population.

(See top link for entire paper)

_____________

For more:

Category:

Activism, Lyme, Psychological Aspects, research, Uncategorized

Hygromycin A Moving to Human Trials

A NEW TREATMENT FOR LYME DISEASE

The path to discovery

In 2015, GLA funded a drug discovery program with Dr. Kim Lewis at Northeastern University, leading to the discovery of hygromycin A, an overlooked antibiotic from 1953. Fast forward to 2021, and Dr. Lewis’s lab revealed that hygromycin A is highly effective against Lyme bacteria and can potentially cure early Lyme disease and prevent chronic conditions.

Building upon this discovery, GLA proudly partnered with Dr. Lewis and Flightpath Biosciences, a biotechnology company. GLA Chief Scientific Officer Timothy Sellati, Ph.D., says, “Flightpath Biosciences will usher hygromycin A along the commercialization path, through clinical trials and FDA approval, ultimately reaching physicians.” Remarkably, not only does hygromycin A kill the Lyme bacteria in the test tube and in animal studies but unlike antibiotics such as doxycycline, it is unlikely to harm the ‘good’ bacteria in a patient’s intestines.

Today, GLA is excited to announce that hygromycin A (FP-100) is moving into the clinic in Q1 2024 for human clinical trials. CEO of Flightpath Biosciences, Matt Tindall, emphasizes, “This landmark achievement for Lyme patients could not have been reached without the kind and generous financial support of GLA and its community.” 

We eagerly anticipate progress and the road ahead, working together to bring hygromycin A (FP-100) into the hands of physicians.

_________________

**Comment**

While not diminishing the potential importance of this, it’s use in preventing or treating persistent infections was not determined.  The subset of patients with chronic debilitating symptoms continues to be ignored.  

For more:

Category:

Lyme, research, Treatment

Ellen Cutler Method Podcast

https://www.betterhealthguy.com/episode191  Go here for article, video, and transcript

Episode #191: Ellen Cutler Method with Dr. Ellen Cutler, DC

 

Why You Should Listen

In this episode, you will learn about the components of the Ellen Cutler Method including detoxification, enzymes, and desensitization.

About My Guest

My guest for this episode is Dr. Ellen Cutler.  Ellen Cutler, DC is a bestselling author and an internationally recognized teacher, public speaker, and media spokesperson.  Her books include “Micro Miracles — Discover the Healing Power of Enzymes,” coming soon in a revised, expanded edition.  She has a chiropractic degree and specializes in the use of desensitization of food and other sensitivities, gentle detoxification, and enzyme and nutritional therapies for chronic conditions that have perplexed the conventional medical establishment. This is all addressed in her revolutionary healing technique the Ellen Cutler Method (ECM).

Key Takeaways

  • What are the components of the Ellen Cutler Method?
  • What is the role of organ-specific drainage?
  • How does the nervous system impact our ability to detoxify?
  • Might exposure to EMFs impact our detoxification ability?
  • What is the connection between environmental toxicants and being overweight?
  • How might digestive enzymes reduce food sensitivities?
  • Can digestive enzymes maximize the potential of our supplement protocols?
  • Is there a role for proteolytic or fibrinolytic enzymes in optimizing health?
  • What factors lead to becoming sensitized?
  • What is the process of desensitization?
  • Can people react to the frequency or energetics of a substance?
  • Can desensitization to our supplements potentially improve their effectiveness?
  • Is it possible to desensitize one to microbes within the body?
  • Is there a place for desensitization in the mold and mycotoxin landscape?

Connect With My Guest

http://DrEllenCutler.com

Category:

Detoxing, Supplements